A Study to Determine the Effect of Multiple Oral Doses and Regimens of KD025 in Healthy Male and Post-menopausal Female Subjects
- Conditions
- Immune System Disorder (Healthy Volunteer)
- Interventions
- Drug: Placebo
- Registration Number
- NCT05918588
- Lead Sponsor
- Kadmon, a Sanofi Company
- Brief Summary
The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of multiple oral doses and regimens of KD025 in healthy male and post-menopausal female participants.
- Detailed Description
Up to approximately 37 days including safety follow up period of 30 days after participant is treated with the last dose of study drug.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 32
- Healthy participants between the ages of 18 and 55 years, inclusive.
- Female who was not of reproductive potential.
- Able to provide written informed consent prior to the performance of any study specific procedures.
- Body mass index (BMI) range of 19-30 kilogram per square meter (kg/m2), inclusive.
- Past or present disease that is judged by the investigator to have the potential to interfere with the study procedures, compromise safety, or affect the PK evaluations.
- Known sensitivity to Rho-associated coiled-coil containing serine/threonine protein kinases (ROCK2) inhibitor agents or to any of the constituents of the KD025 formulation.
The above information is not intended to contain all considerations relevant to the potential participation in a clinical trial.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description Cohort 3 Placebo 500 mg KD025 or placebo twice daily (BID) for 7 days Cohort 2 Placebo 800 mg KD025 or placebo QD for 7 days Cohort 1 Placebo 500 mg KD025 or placebo once daily (QD) for 7 days Cohort 4 Placebo 1000 mg KD025 or placebo QD for 7 days Cohort 3 Belumosudil mesylate 500 mg KD025 or placebo twice daily (BID) for 7 days Cohort 4 Belumosudil mesylate 1000 mg KD025 or placebo QD for 7 days Cohort 1 Belumosudil mesylate 500 mg KD025 or placebo once daily (QD) for 7 days Cohort 2 Belumosudil mesylate 800 mg KD025 or placebo QD for 7 days
- Primary Outcome Measures
Name Time Method Number of participants with adverse events and serious adverse events Up to approximately 37 days Safety observations and measurements include AEs, safety laboratory tests, vital sign measurements, physical examinations, and ECGs.
- Secondary Outcome Measures
Name Time Method Cmax of KD025 and its metabolites [M1 (KD025m1) and M2 (KD025m2)] Predose and multiple timepoints up to 48 hours postdose on Days 1 and 7 Cmax is maximum plasma concentration determined directly from the concentration time profile
tmax of KD025 and its metabolites [M1 (KD025m1) and M2 (KD025m2)] Predose and multiple timepoints up to 48 hours postdose on Days 1 and 7 tmax is observed time to reach peak plasma concentration
AUC0-24 of KD025 and its metabolites [M1 (KD025m1) and M2 (KD025m2)] Predose and multiple timepoints up to 48 hours postdose on Days 1 and 7 AUC0-24 is area under the plasma concentration-time curve from predose (time 0) to 24 hours Postdose
AUCinf of KD025 and its metabolites [M1 (KD025m1) and M2 (KD025m2)] Predose and multiple timepoints up to 48 hours postdose on Days 1 and 7 AUCinf is area under the concentration-time curve from predose (time 0) extrapolated to Infinity
Cmin of KD025 and its metabolites [M1 (KD025m1) and M2 (KD025m2)] Predose and multiple timepoints up to 48 hours postdose on Days 1 and 7 Cmin is minimum or "trough" plasma concentration after its administration and just prior to the administration of a subsequent dose as determined from the concentration time profile
t1/2 of KD025 and its metabolites [M1 (KD025m1) and M2 (KD025m2)] Predose and multiple timepoints up to 48 hours postdose on Days 1 and 7 t1/2 is terminal elimination half-life
Trial Locations
- Locations (1)
Investigational site
🇺🇸Buffalo, New York, United States